Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CTSB
REST API REST API
Homo sapiens
CTSB is differentially expressed in 368 experiments: 147 organism parts: liver, kidney, ... (145 more);, 271 disease states: normal, glioblastoma, ... (269 more);, 148 cell types 560 cell lines 61 compound treatments and 86 other conditions.
Orthologs Ctsb (Mus musculus)   Ctsb (Rattus norvegicus)   ctsba (Danio rerio)   F1N9D7_CHICK (Gallus gallus)   CATB_BOVIN (Bos taurus)   ctsbb (Danio rerio)   CG10992 (Drosophila melanogaster)   ctsb (Xenopus laevis)   CTSB (Canis familiaris)   (Compare orthologs)
InterPro Term Peptidase_C1A_C, Propeptide_C1A
Gene Ontology Term protein binding, response to wounding, cytoplasm, intracellular, extracellular space, regulation of catalytic activity, lysosome, peptidase activity, response to stress, extracellular region, sarcolemma, external side of plasma membrane, soluble fraction, cysteine-type endopeptidase activity, peptide binding, endopeptidase activity, perinuclear region of cytoplasm, apical plasma membrane, proteolysis, cell surface, response to ethanol, skeletal muscle tissue development, autophagy, cysteine-type peptidase activity, response to mechanical stimulus, caveola, mitochondrion, regulation of apoptosis, kininogen binding, response to amine stimulus, response to interleukin-4, response to peptide hormone stimulus, negative regulation of cell death, response to glucose stimulus, melanosome, response to organic cyclic compound
UniProt Accession P07858, Q8TAC7, B4DMY4, E9PNL5, E9PR00, E9PQM1, E9PSG5, E9PS78, E9PR54, E9PCB3, E9PHZ5, E9PID0, E9PIS1, E9PJ67, E9PKD0, E9PKQ7, E9PL32, E9PKX0, E9PLY3, F5H2P9
Search EB-eye ENSG00000164733
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (50 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
SW480
1
3
E-MTAB-37, E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
BT-474
2
E-GEOD-3529, E-GEOD-5823
DU145
2
E-GEOD-17482, E-GEOD-20089
KG1
2
E-GEOD-24147, E-MTAB-37
MOLT4
2
E-MTAB-37, E-MTAB-62
554 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (69 experiments)

Factor Value U/D Experiments
CD14+ monocyte
3
E-AFMX-5, E-TABM-145, E-MEXP-1600
monocyte
3
5
E-GEOD-11755, E-MEXP-583, E-GEOD-22373, E-MEXP-2019, E-GEOD-5099, ... (8 experiments)
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
mononuclear
2
E-GEOD-13987, E-GEOD-26672
neutrophil
1
2
E-GEOD-3982, E-GEOD-12662, E-GEOD-995
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
142 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-1577, E-MTAB-62, ... (75 experiments)

Factor Value U/D Experiments
glioblastoma
6
E-GEOD-6014, E-GEOD-4290, E-MTAB-37, E-GEOD-4412, E-MEXP-567, ... (6 experiments)
prostate carcinoma
4
E-MEXP-2034, E-MEXP-1327, E-MTAB-62, E-TABM-26
benign prostatic hyperplasia
3
E-MEXP-2034, E-MEXP-1243, E-GEOD-3868
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20602, E-GEOD-16728
AIDS-KS, HIV+, nodular (late) stage
1
2
E-MTAB-62, E-MEXP-66
265 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (31 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
placebo
2
E-MEXP-1335, E-MEXP-1327
sapphyrin PCI-2054
1
E-GEOD-6400
4,5-dianilinophthalimide
2
1
E-GEOD-5258
sapphyrin PCI-2051
1
E-GEOD-6400
ZMYM2/FGFR1
1
E-GEOD-15811
55 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd3
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, E-GEOD-19348, ... (11 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-MTAB-69, ... (10 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (11 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-22593, E-GEOD-20115, E-TABM-868, E-TABM-601, ... (15 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-MEXP-1648, ... (40 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-7179

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-22229, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, ... (11 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-MEXP-1422, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, ... (10 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-7307

Sirna
studied in E-GEOD-21574

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-22152, E-GEOD-16837, E-MEXP-973, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.489 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM